SVB Leerink and Pfizer

Selected healthcare news for the capital firm - SVB Leerink, and the company - Pfizer. We have 188 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
12/30/2021 Barclays Reiterates ‚Äú$54.00‚Äù Price Target for Pfizer (NYSE:PFE) Dakota Financial News Pfizer (NYSE:PFE) has been assigned a $54.00 price objective by Barclays in a research report issued on Wednesday, Borsen Zeitung reports. Barclays ‚Aos target price suggests a potential downside of 6.22% from the stock ... of Pfizer in a research report on Friday, November 5th. SVB Leerink lifted their price objective on Pfizer from $52.00 to $56.00 and gave the company a ‚Aumarket perform‚Au rating in a research report ...
12/29/2021 Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers | FiercePharma FiercePharma ... Pfizer will face two major issues. All three companies will have a large portion of their 2025 revenues exposed to generic or biosimilar competition, and they will also see those revenues erode quickly, an SVB Leerink team led by analyst Geoffrey Porges said in a Monday note to clients.BMS, Amgen and Pfizer will likely see copycats eat away 47%, 29% and 28% of their respective anticipated 2025 total revenues ...
12/14/2021 Arena Pharma (ARNA) to be acquired by Pfizer (PFE) for $100/share or $6.7B Pfizer has agreed to buy U.S. biotech company Arena Pharmaceuticals in a deal valued at about $6.7 billion.- The U.S. pharma giant said the acquisition would expand its cancer and inflammatory disease drug pipeline.Analysts ... benefit from the executional expertise of a large pharmaceutical company," SVB Leerink analyst Joseph Schwartz told analysts in a research note. "PFE's commercial framework can capitalize on etrasimod's best-in-class potential," wrote RBC Capital ...
12/13/2021 Analysts: Pfizer to 'capitalize' on experimental colitis treatment in Arena deal | Markets Insider Business Insider ... Pfizer Inc.'s plans to acquire Arena Pharmaceuticals Inc. in a deal worth $6.7 billion and announced Monday morning. Pfizer's stock was up 1.2% in premarket trading on Monday, while shares of Arena soared 88.3%. "We view PFE as a logical partner for ARNA as the latter continues to progress its gastroenterology, dermatology, and cardiology focused platform, which should benefit from the executional expertise of a large pharmaceutical company," SVB ...
12/7/2021 Watch out, Pfizer and Alnylam. AstraZeneca wades deeper into rare diseases with Ionis tie-up | FiercePharma FiercePharma ... AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmaceuticals, targeting a condition where Pfizer and Alnylam are also competing.For $200 million upfront, AstraZeneca is licensing Ionis‚Ao ... Street thinks eplontersen can generate $1.3 billion in 2030 sales, SVB Leerink analyst Mani Foroohar said in an October note to clients.An estimated 300,000 to 500,000 patients have ATTR around the globe, according to ...
12/6/2021 Vaccine Stocks Crumble After Omicron 'Exploded' In South Africa | Investor's Business Daily ... Moderna ( MRNA ) crumbled Monday as early reports suggested the omicron variant might lead to less severe cases of Covid.X SVB Leerink analyst Geoffrey Porges examined cases in South Africa. Although the rate of positive ... with the world. Last week, a handful of investors in Pfizer and Moderna "become $10 billion richer as news about the omicron variant spread," he tweeted.IBD Newsletters Get exclusive IBD analysis and actionable news ...
12/3/2021 Pfizer's Set to Make $131 Billion in COVID Sales in 2 Years. Is the Stock a Buy? | Nasdaq Nasdaq ... Pfizer (NYSE: PFE) . The company reported $13 billion in sales of its COVID-19 vaccine Comirnaty in the third quarter alone. SVB Leerink analyst Geoffrey Porges estimates that Pfizer is set to make a stunning $131 billion in COVID-19 sales by the end of 2022. But is the pharmaceutical stock a buy?Image source: Getty Images.Crunching the numbers Let's first look at how Pfizer could make $160 billion ...
12/3/2021 Pfizer's Set to Make $131 Billion in COVID Sales in 2 Years. Is the Stock a Buy? - NewsBreak ... Pfizer (NYSE: PFE) . The company reported $13 billion in sales of its COVID-19 vaccine Comirnaty in the third quarter alone. SVB Leerink analyst Geoffrey Porges estimates that Pfizer is set to make a stunning $131 billion in COVID-19 sales by the end of 2022. But is the pharmaceutical stock a buy?Image source: Getty Images.Crunching the numbers Let's first look at how Pfizer could make $160 billion ...
11/29/2021 Merck Gives Up 2021 Gains Ahead of Covid Pill Panel Review Yahoo News ... Pfizer Inc.‚Aos antiviral.SVB Leerink analyst Daina Graybosch expects the FDA panel will focus on the issues seen in Merck‚Aos pill, including ‚Aurisk of harm to fetuses and accelerated viral mutation rate that may drive emergence of new SARS-CoV-2 variants, in addition to relatively weaker efficacy,‚Au she wrote in a research note.Demand for antivirals for the profitable government stockpiles will shift to Pfizer over ...
9/29/2021 IBD stock of the day flashes another sell signal ... Pfizer (PFE) sent data to the Food and Drug Administration to support their vaccine in children ages 5-11. US officials recently authorized their Covid booster injection for the elderly and those at risk of developing severe Covid. SVB Leerink analyst Geoffrey Porges called it ‚Auopen season‚Au on boosters. He expects vaccination centers, clinics and pharmacies to be inundated with vaccination appointments for ‚Authe concerned people‚Au and people who ...
9/25/2021 Why It's Now ‚ÄòOpen Season‚Äô For Pfizer-BioNTech Covid Boosters ... for elderly and otherwise vulnerable adults. But vaccine stocks dipped. X The full CDC will allow certain recipients of the Pfizer ( PFE )-BioNTech ( [BNTX ... care workers and teachers, as well as residents of prisons. SVB Leerink analyst Geoffrey Porges says the ‚Auunprecedented and highly controversial move‚Au will open up booster shots to all Pfizer-BioNTech recipients. Adults merely ...
9/24/2021 Why It's Now ‚ÄòOpen Season‚Äô For Pfizer-BioNTech Covid Boosters ... elderly and otherwise vulnerable adults. But some vaccine stocks dipped. X The full CDC will allow certain recipients of the Pfizer ( PFE )-BioNTech ( [BNTX ... care workers and teachers, as well as residents of prisons. SVB Leerink analyst Geoffrey Porges says the ‚Auunprecedented and highly controversial move‚Au will open up booster shots to all Pfizer-BioNTech recipients. Adults merely ...
9/24/2021 Vaccine Stocks: Why It's Now 'Open Season' For Pfizer-BioNTech Covid Boosters | Investor's Business Daily ... elderly and otherwise vulnerable adults. But some vaccine stocks dipped.X The full CDC will allow certain recipients of the Pfizer ( PFE )- BioNTech ( BNTX ) vaccine to receive a booster shot at six months. That group ... care workers and teachers, as well as residents of prisons.SVB Leerink analyst Geoffrey Porges says the "unprecedented and highly controversial move" will open up booster shots to all Pfizer-BioNTech recipients. Adults merely have ...
9/23/2021 Pfizer Nabs Booster OK For Some; But Will It Keep Its Covid Lead? Vaccine stocks popped Thursday after the Food and Drug Administration authorized Pfizer ( PFE ) and BioNTech‚Aos ( BNTX ) Covid booster shot for at-risk groups. X The new ... boosters. The panel began meeting Wednesday to discuss booster shots, SVB Leerink analyst Geoffrey Porges said in a note to clients. Panelists are expected to vote today. ‚AuThe ACIP seemed less concerned about the loss ...
9/23/2021 Pfizer Nabs Booster OK For Some; But Will It Keep Its Covid Lead? Vaccine stocks popped Thursday after the Food and Drug Administration authorized Pfizer ( PFE ) and BioNTech‚Aos ( BNTX ) Covid booster shot for at-risk groups. X The new ... boosters. The panel began meeting Wednesday to discuss booster shots, SVB Leerink analyst Geoffrey Porges said in a note to clients. Panelists are expected to vote today. ‚AuThe ACIP seemed less concerned about the loss ...
9/18/2021 SVB Leerink Reaffirms ‚ÄúHold‚Äù Rating for Pfizer (NYSE:PFE) SVB Leerink restated their hold rating on shares of Pfizer (NYSE:PFE) in a research report report published on Tuesday, Analyst Ratings Network reports. The brokerage currently has a $49.00 price objective on the biopharmaceutical company‚Aos stock. PFE has been the topic of a number of other reports. JPMorgan Chase & Co. raised their price objective on shares of Pfizer from $40.00 to $42.00 and gave the company a neutral ...
9/17/2021 Vaccine Stocks Plunge As Booster Opportunity Seen Slipping Away ... booster shots. X Evercore ISI analyst Umer Raffat doesn‚Aot expect the FDA advisory committee to vote in support of Pfizer (PFE) and BioNTech‚Aos Covid booster shot. Later today, the panel of experts will ... shot opportunity could be huge for vaccine stocks. On Thursday, SVB Leerink analysts estimated the opportunity could be worth $3 billion to $4 billion in the U.S. alone. But much of that opportunity is already ...
9/17/2021 Vaccine Stocks Plunge As Booster Opportunity Seen Slipping Away ... booster shots.XEvercore ISI analyst Umer Raffat doesn‚Aot expect the FDA advisory committee to vote in support of Pfizer (PFE) and BioNTech‚Aos Covid booster shot. Later today, the panel of experts will ... shot opportunity could be huge for vaccine stocks. On Thursday, SVB Leerink analysts estimated the opportunity could be worth $3 billion to $4 billion in the U.S. alone. But much of that opportunity is already ...
9/17/2021 Why The FDA Is Likely To Sign Off On Covid Boosters ‚Äî With Some Caveats Booster shots could expand the opportunity for Covid vaccine stocks like Pfizer ( PFE ) and Moderna ( MRNA ) by $3 billion to $4 billion in the U.S. alone, according to one estimate. X The estimate from investment bank SVB Leerink comes a day ahead of a key meeting by the Food and Drug Administration‚Aos vaccines advisory committee. The panel of independent experts will ...
9/16/2021 Pfizer (NYSE:PFE) Stock Rating Reaffirmed by SVB Leerink Dakota Financial News Pfizer (NYSE:PFE)‚Aos stock had its ‚Auhold‚Au rating restated by investment analysts at SVB Leerink in a research note issued on Tuesday, PriceTargets.com reports. They currently have a $49.00 price target on the biopharmaceutical company‚Aos stock. SVB Leerink‚Aos price objective indicates a potential upside of 9.45% from the company‚Aos previous close. Several other analysts have also issued reports on the stock. Berenberg Bank reiterated a ...
9/13/2021 Pharma's JAK drugs could suffer in rheumatoid arthritis, atopic dermatitis. How do FDA warnings affect other inflammatory uses? FiercePharma After the FDA last week slapped safety warnings and use restrictions on AbbVie‚Aos Rinvoq, Eli Lilly‚Aos Olumiant and Pfizer‚Aos Xeljanz, Wall Street has started rethinking its calculations for the JAK inhibitor class.Based on discussions with three industry experts, analysts with SVB Leerink believe the FDA‚Aos warning could have a range of effects on the meds‚Ao opportunities across inflammatory diseases.JAKs could see big use ...
9/10/2021 FY2023 Earnings Estimate for Pfizer Inc. Issued By SVB Leerink (NYSE:PFE) - WKRB News Pfizer Inc. (NYSE:PFE) ‚Ai Equities research analysts at SVB Leerink lifted their FY2023 earnings estimates for Pfizer in a research note issued on Tuesday, September 7th. SVB Leerink analyst G. Porges now forecasts that the biopharmaceutical company will earn $3.37 per share for the year, up from their previous forecast of $3.34. SVB Leerink currently has a ‚AuMarket Perform‚Au rating and a $49.00 target price on the stock ...
9/10/2021 Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business ... Pfizer Inc. ( PFE , Financial ) raking in $2.1 billion, Johnson & Johnson ( JNJ , Financial ) adding $1.7 billion to its top line and Sanofi SA ( SNY , Financial ) pocketing $1.2 billion. Vaccine developers have been trying to come up with a shot for RSV for years with no success. It appears that‚Aos about to change, SVB Leerink analyst ...
9/9/2021 Why Atea Could Be the Frontrunner in the Covid Antiviral Race | Barron's ... SVB Leerink.Atea (ticker: AVIR) is one of a number of companies developing Covid-19 antivirals, amid an emerging consensus that the virus that causes Covid-19 will remain a global health challenge for the long-term.Big pharma giants Merck (MRK) and Pfizer (PFE) both are developing their own Covid-19 antiviral pills, but SVB Leerink analyst Roanna Ruiz writes in her Thursday note that the Covid-19 therapeutic ...
9/8/2021 GSK, Pfizer and Johnson & Johnson race toward $10B+ RSV vaccine market: analyst FiercePharma ... Pfizer, Johnson & Johnson and GlaxoSmithKline are expected to be involved .RSV, or respiratory syncytial virus, has long been a top target for vaccine developers. While companies have suffered high-profile trial failures over the years, vaccines are now advancing through late-stage testing and could launch in 2023, SVB Leerink analyst Geoffrey Porges wrote to clients this week.As companies race to the FDA finish line, a market worth $10.5 ...